title: IgE immunotherapy: a novel concept with promise for the treatment of cancer.
abstract: The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the IgE class can confer natural, potent, long-lived immune surveillance in tissues through tenacious engagement of high-affinity cognate Fc receptors on distinct, often tumor-resident immune effector cells, and through ability to activate these cells under tumor-induced Th2-biased conditions. Here, we review the properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites, which also support IgE as a novel anti-cancer modality. We discuss IgE-based active and passive immunotherapeutic approaches in disparate in vitro and in vivo model systems, collectively suggesting the potential of IgE immunotherapies in oncology. Translation toward clinical application is now in progress.
authors.affiliation: Cutaneous Medicine and Immunotherapy Unit; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK; Division of Cancer Studies; King's College London; Guy's Hospital; London, UK.
authors.forename: Debra H
authors.initials: DH
authors.lastname: Josephs
authors.affiliation: Division of Cancer Studies; King's College London; Guy's Hospital; London, UK.
authors.forename: James F
authors.initials: JF
authors.lastname: Spicer
authors.affiliation: Cutaneous Medicine and Immunotherapy Unit; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Karagiannis
authors.affiliation: Randall Division of Cell and Molecular Biophysics & Division of Asthma; Allergy and Lung Biology; MRC and Asthma UK Centre for Allergic Mechanisms of Asthma; King's College London; Guy's Campus; London, UK.
authors.forename: Hannah J
authors.initials: HJ
authors.lastname: Gould
authors.affiliation: Cutaneous Medicine and Immunotherapy Unit; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK.
authors.forename: Sophia N
authors.initials: SN
authors.lastname: Karagiannis
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents; D006801:Humans; D007116:Immunization, Passive; D007073:Immunoglobulin E / Q000276:immunology / Q000627:therapeutic use; D007157:Immunologic Surveillance / Q000187:drug effects*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007073:Immunoglobulin E
keywords: AllergoOncology; IgE; IgE immunotherapy; antibodies; antibody effector functions; cancer immunotherapy